Beyond Capacity: Redefining Sponsor Expectation

As biopharmaceutical pipelines increasingly pivot toward advanced, highly complex modalities, sponsors’ demands placed on CDMOs are undergoing a transformation.
Listen on your preferred platform here.
For decades, traditional small- and large-molecule outsourcing relied on established manufacturing frameworks where compliance, baseline safety, and predictable scale-up constituted the primary benchmarks. However, the emergence of complex modalities is introducing vastly different supply chain, analytical, and delivery requirements.
“As the biopharmaceutical pipelines shift towards new advanced highly complex modalities, such as cell and gene therapies and in vivo CAR-T, obviously the expectations on the CDMO providers have drastically shifted,” reveals Behnam Ahmadian Baghbaderani, Global Head of Sales, Business Development and Account Management for Specialized Modalities at Lonza. “Sponsors have moved away from purely focusing on capacity availability and timeline to now expecting CDMOs to have more knowledge, know-how, and expertise to be able to anticipate how these new modalities will evolve.”
Click above to listen to the full conversation in the latest episode of All Points of the Pharma Compass.
Technical Differentiation
There is now an impetus for CDMOs to be able to integrate capabilities across development and manufacturing and to adapt rapidly as programs move from the clinical to commercial stages, Baghbaderani continues. Such flexibility requires manufacturing models, analytical frameworks, and supply chain strategies that differ from conventional platforms, he notes.
“Specialized expertise is now the entry point when it comes to the CDMO and service providers,” Baghbaderani asserts. “The main differentiating factor is how the service provider can translate this expertise into faster, more predictable development and manufacturing. Leading CDMOs, for example, would need to demonstrate that they have adaptable process development platforms, fit-for-purpose analytics, risk-based approaches towards development and manufacturing, characterization strategies, and automation and technologies that can reduce the cycle time without compromising on quality.”
Baghbaderani emphasizes the strategic advantage of taking a technology-agnostic approach, where solutions are continuously evaluated and implemented based on the need of the molecule, the product, and the patient rather than forcing diverse pipelines into rigid, proprietary platforms. “What ultimately differentiates a CDMO from other CDMOs or a leading CDMO is not the presence of individual tools, but the ability to integrate them into a scientifically sound, scalable, robust, and reliable, regulatory-ready development path and the manufacturing process,” he says.
The Power of Development
In the advanced therapy space, bottlenecks in process development and analytical testing frequently lead to costly delays or late-stage failures. According to Baghbaderani, achieving long-term commercial viability requires prioritizing the “D” in development just as rigorously as the “M” in manufacturing.
“When it comes to CDMOs, I’ve seen that there is a lot of focus on ‘M’; however, I’ve learned that the ‘D’ is actually very important and can help de-risk the manufacturing side of the focus,” Baghbaderani stresses. “The most effective CDMOs, from my perspective, engage early on, defining the target process and control the strategy with commercialization in mind and identifying a scale-out, raw material choice of technology, analytics, and automation that are required to de-risk the path from early clinical to commercial. A process may be adequate for Phase I, preclinical or Phase I, but If the choice of the technology, the type of bioreactor expansion, unit operation or analytical method has not been chosen properly that fit the eventual scaling and commercially viable solution, it will eventually face significant roadblocks or even fail.”
Choosing the correct unit operations, 2D versus 3D systems, raw materials, and robust analytical assays, including critical identity, safety, potency, and functionality assessments, early in the lifecycle prevents potential roadblocks later down the line, Baghbaderani comments. For example, pioneering scalable three-dimensional, computer-controlled bioreactor processes (such as scaling complex cell therapies up to 50 liters) demonstrates how early strategic decisions enable smooth transitions to commercial scale, he highlights.
Integrating Digital Tools and AI
As the industry looks for ways to optimize workflows, data-driven technologies like artificial intelligence (AI)-assisted analytics, predictive modeling, and automated in-process monitoring are gaining traction, Baghbaderani confirms. When applied alongside deep scientific and engineering expertise, digital tools can drastically improve process understanding, reduce variability, and accelerate development cycles, he specifies.
“The market is still struggling where the digital initiatives are introduced without sufficient data quality, system integration, validation strategy, or a measurable business and patient impact. In a regulated environment, adoption must also be transparent, secure, and fit for purpose,” Baghbaderani explains. “The leaders in the field and the CDMO leaders are the providers that can combine the digital capabilities with domain expertise and disciplined implementation, and they can turn the data into faster, more robust and reliable, and more scalable outcomes for the customers and therapeutic applications.”
Fostering Collaboration to Meet Future Needs
As the industry continues to evolve, strategic partnerships remain critical for addressing emerging market gaps. Highlighting ongoing efforts to align with industry shifts, such as the transition from ex vivo cell therapies to in vivoapplications, Baghbaderani points to Lonza’s recent collaboration with Asimov to shape the development and manufacturing pathway for in vivo lentiviral vector applications (1).
By equipping development frameworks with cutting-edge vector technologies, such partnerships aim to provide sponsors with enhanced vector performance, superior manufacturability, and accelerated timelines that meet stringent regulatory expectations, Baghbaderani summarizes.
Reference
1. Lonza. Lonza and Asimov Collaborate to Advance In Vivo Lentiviral Vector Manufacturing. Press Release, Oct. 2, 2026.
About the Interviewee
Behnam Ahmadian Baghbaderani, is the Global Head of Sales, Business Development and Account Management for Specialized Modalities at Lonza. Behnam has worked at Lonza for over 15 years and has more than 28 years of industry experience in developing and establishing processes for customers. He is a bioprocess engineer, stem cell engineer by training and is currently focusing on offering technologies and services that are available for customers actively seeking to develop and commercialize therapies within the scope of specialized modalities.
Music: ‘Over The Horizon’ by Roo Walker on #Uppbeat https://uppbeat.io/c/roo-walker
License code: WXJ2YB0C7BQ53FXZ
Image Credit: © GoodIdeas – stock.adobe.com










